MILabs announced today that it has successfully completed the installation of its top-of-the-line multimodality PET-SPECT-UHR CT in the laboratory of Prof. Maiken Nedergaard, M.D, D.M.Sci. - Center for Translational Neuroscience, Division of Glial Disease and Therapeutics.
UTRECHT, THE NETHERLANDS, February 5, 2018
MILabs announced today that it has successfully completed the installation of its top-of-the-line multimodality PET-SPECT-UHR CT in the laboratory of Prof. Maiken Nedergaard, M.D, D.M.Sci. – Center for Translational Neuroscience, Division of Glial Disease and Therapeutics.
Prof. Nedergaard is one of the most renowned names in neuroscience who discovered the glymphatic system - the brain equivalent of the lymphatic system – while working at the University of Rochester Medical Center. She is now a professor at University of Copenhagen’s Center of Basic and Translational Neuroscience.
The installed MILabs PET/SPECT/CT system is the latest VECTor/CT multimodality system featuring industry-leading molecular, functional and anatomical tomographic imaging capabilities including 0.6 mm PET, 0.14 mm ex-vivo Exirad-SPECT and 0.25 mm in-vivo SPECT, and 3D/4D CT imaging with 4µm voxel-resolutions.
The Center for Translational Medicine is a world-class institute in brain research, specialized in cerebrospinal fluid (CSF) fluid dynamics and protein clearance, and its dysregulation effect on neurodegenerative disorders, including Alzheimer’s disease.
Dr. Maiken Nedergaard,, whose division focuses on astrocytic physiology and pathology, stated: " This new instrument will facilitate our research of cerebral blood flow and its glial regulation, so that disorders long thought neuronal in nature can now be investigated as disorders principally of glial cells, including both astrocytes and oligodendrocytes as well as their progenitors”
Prof. Frederik Beekman, Ph.D., CEO of MILabs B.V., added: “We are extremely pleased to provide enabling ultra-high resolution Exirad-3D and VECTor/CT molecular and functional research tools allowing the Glial Disease and Therapeutics lab for further explore the development of new CNS diagnostic and therapeutic methods based on glial biology”
About the University of Copenhagen:
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is one of the largest institutions of research and education in the Nordic countries. A merger with The Royal Veterinary and Agricultural University and The Danish University of Pharmaceutical Sciences in 2007 has led to the formation of one of the largest Health and Life Science centers in Northern Europe consisting of the Faculty of Health and Medical Sciences and the Faculty of Science: http://www.ku.dk/english/
The University of Copenhagen is also a member of IARU (International Alliance of Research Universities). The alliance consists of ten universities worldwide: Australian National University, ETH Zürich, National University of Singapore, Peking University, University of California, Berkeley, University of Cambridge, University of Copenhagen, University of Oxford, The University of Tokyo, and Yale University.
About MILabs:
MILabs B.V. (Utrecht, the Netherlands) provides high-end integrated multimodality imaging solutions for biomedical and pharmaceutical research, designed to deliver high-definition molecular, functional and anatomical images. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. For more information, visit www.milabs.com or contact MILabs at info@milabs.com
